Covalent Group, Inc. Retains The Equity Group to Provide Investor Relations Services
31 Janeiro 2006 - 3:00PM
Business Wire
Covalent Group, Inc. (NASDAQ: CVGR), a clinical research
organization that is a leader in the design and management of
complex clinical trials and patient disease registries for the
pharmaceutical, biotechnology and medical device industries today
announced that it has retained The Equity Group Inc. to provide
investor relations services for the Company. Kenneth M. Borow,
M.D., Covalent Group's President and Chief Executive Officer,
stated, "We are proud of our position as a leader in the design and
management of complex clinical trials and Patient Disease
Registries for the pharmaceutical, biotechnology and medical device
industries. We have established an excellent reputation with our
clients across a wide range of therapeutic areas based on the high
quality of our consulting and operational services. Our top
strategic priorities for 2006 are to expand our reach into new
geographic areas of operations, to provide additional programmatic
services to our clients, and to significantly increase our top-line
revenues and profitability." Dr. Borow continued, "Indicative of
the strong confidence that we have in our business going forward,
we have retained The Equity Group to help communicate our
accomplishments, strategic objectives, and outlook to a much larger
and more diverse group of investment professionals and financial
media. The Equity Group came highly recommended as a respected,
experienced, and results-driven investor relations firm. We were
impressed by the caliber, longevity, and references of their
clients and are confident that they will do an excellent job
representing us to the financial community." About The Equity Group
Inc. The Equity Group Inc., which was founded in 1974, provides a
full spectrum of investor and financial public relations services
primarily to growth companies listed on the Nasdaq, American and
New York Stock Exchanges. For more information, visit
www.theequitygroup.com. About Covalent Group, Inc. Covalent Group,
Inc. is a clinical research organization that is a leader in the
design and management of complex clinical trials and Patient
Disease Registries for the pharmaceutical, biotechnology and
medical device industries. The Company's mission is to provide its
clients with high quality, full-service support for their
biopharmaceutical development programs. Covalent offers therapeutic
expertise, experienced team management and advanced technologies.
The Company has drug and biologics development as well as clinical
trial experience across a wide variety of therapeutic areas such as
cardiovascular, endocrinology/metabolism, diabetes, vaccines,
infectious diseases, gene therapy, immunology, neurology, oncology,
gastroenterology, dermatology, hepatology, women's health and
respiratory medicine. Covalent believes that its leadership in the
design of complex clinical trials, its therapeutic expertise and
commitment to excellence, and its application of innovative
technologies, offer its clients a means to more quickly and cost
effectively move products through the clinical development process.
With its wholly-owned international subsidiary, Covalent Group,
Ltd., as well as its Strategic Partners operating in various
regions around the world, Covalent is able to meet the global drug
development needs of its clients. For more information, please
visit www.covalentgroup.com. This press release contains
forward-looking statements identified by words such as "estimate,"
"project," "expect," "intend," "believe," "anticipate" and similar
expressions. Actual results might differ materially from those
projected in, expressed in or implied by the forward-looking
statements. Potential risks and uncertainties that could affect the
Company's future operating results and financial condition include,
without limitation: (i) our success in attracting new business and
retaining existing clients and projects; (ii) the size, duration,
and timing of clinical trials we are currently managing may change
unexpectedly ; (iii) the termination, delay or cancellation of
clinical trials we are currently managing could cause revenues to
decline unexpectedly; (iv) the timing difference between our
receipt of contract milestone or scheduled payments and our
incurring costs to manage these trials; (v) outsourcing trends in
the pharmaceutical, biotechnology and medical device industries;
(vi) the ability to maintain profit margins in a competitive
marketplace; (vii) our ability to attract and retain qualified
personnel; (viii) the sensitivity of our business to general
economic conditions; (ix) other economic, competitive, governmental
and technological factors affecting our operations, markets,
products, services and prices; (x) announced awards received from
existing and potential customers are not definitive until fully
negotiated contracts are executed by the parties; and (xi) our
backlog may not be indicative of future revenues and may not
generate the revenues expected. You should not place any undue
reliance on these forward looking statements which speak only as of
the date of this press release. Additional information concerning
factors that might affect our business or stock price which could
cause actual results to materially differ from those in
forward-looking statements is contained in Covalent Group's SEC
filings, including its Annual Report on Form 10-K for the year
ended December 31, 2004 and other periodic reports under the
Securities Exchange Act of 1934, as amended, copies of which are
available upon request from Covalent Group's investor relations
department.
Covalent (NASDAQ:CVGR)
Gráfico Histórico do Ativo
De Set 2024 até Out 2024
Covalent (NASDAQ:CVGR)
Gráfico Histórico do Ativo
De Out 2023 até Out 2024